DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
GSK2256294 is an investigational drug.
There have been 5 clinical trials for GSK2256294. The most recent clinical trial was a Phase 1 trial, which was initiated on May 17th 2018.
The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline, Oregon Health and Science University, and Parexel.
There are two US patents protecting this investigational drug and thirty international patents.
Recent Clinical Trials for GSK2256294
|Soluble Epoxide Hydrolase Inhibition and Insulin Resistance||Vanderbilt University Medical Center||Phase 2|
|Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial||Oregon Health and Science University||Phase 1/Phase 2|
|To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions||Parexel||Phase 1|
Top disease conditions for GSK2256294
Top clinical trial sponsors for GSK2256294
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GSK2256294||Start Trial||sEH inhibitors and their use||GlaxoSmithKline, LLC (Philadelphia, PA)||Start Trial|
|GSK2256294||Start Trial||sEH inhibitors and their use||GlaxoSmithKline LLC. (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|